Shares of Exelixis EXEL moved higher in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 48.00% year over year to $0.37, which beat the estimate of $0.07.
Revenue of $385,177,000 higher by 48.44% from the same period last year, which beat the estimate of $298,160,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Exelixis hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 05, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/f2ewr8h2
Technicals
Company's 52-week high was at $27.35
Company's 52-week low was at $16.19
Price action over last quarter: down 28.51%
Company Overview
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
